AI in drug development

Market Access

Whether a drug can secure reimbursement is pharma's billion-dollar question, and the companies that succeed will be those that answer it sooner.

R&D

The future of drug development is not scientists versus algorithms. It is scientists and algorithms working together.

Digital

With AI, trial sponsors are now reducing risk, accelerating timelines, and driving innovation by modelling what is most likely to work in the future.

News

New analysis from Tufts CSDD and Medable shows AI agent value to oncological drug development programmes at up to $21m each.

News

Seeking an R&D edge, Novo Nordisk has become the latest big pharma group to forge an alliance with tech giant OpenAI.

R&D

As discovery becomes faster and more accessible, the differentiator shifts downstream.